Feng Du, Jiang Huixin, Chen Gengjia, Guan Wenhui, Yi Lin, Zhu Yue, Li Yijia, Huang Gengda, He Bin, Tang Junlong, Tang Yujie, Zeng Jiyuan, Zhou Wensheng, Shi Jiayu, Xie Zhanhong, Liu Ming, Xie Xiaohong, Lin Xinqing, Zhou Chengzhi
Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Nanshan School, Guangzhou Medical University, Guangzhou, Guangdong, China.
Front Immunol. 2024 Dec 9;15:1485358. doi: 10.3389/fimmu.2024.1485358. eCollection 2024.
The STK11 gene mutation is a common genetic alteration in non-small cell lung cancer (NSCLC) and is significantly associated with poor responses to current immunotherapy regimens. Despite its prevalence, there is currently no established standard for front-line treatment in this subtype of NSCLC, underscoring the increasing need for personalized therapeutic strategies. In this report, we present a case of a patient with STK11-mutant NSCLC who was treated with first-line cadonilimab (10mg/kg) in combination with pemetrexed (500mg/m^2) plus carboplatin (AUC=5), resulting in a notable extension of progression-free survival (PFS). This case highlights the potential efficacy and feasibility of combining immunotherapy with chemotherapy in patients with STK11-mutant NSCLC. Additionally, we provide a review of recent advancements in research related to STK11 mutations in lung cancer as reported in the literature.
STK11基因突变是非小细胞肺癌（NSCLC）中常见的基因改变，并且与当前免疫治疗方案的疗效不佳显著相关。尽管其普遍存在，但目前对于这种NSCLC亚型的一线治疗尚无既定标准，这凸显了对个性化治疗策略的需求日益增加。在本报告中，我们介绍了1例STK11突变的NSCLC患者，该患者接受一线卡度尼利单抗（10mg/kg）联合培美曲塞（500mg/m²）加卡铂（AUC=5）治疗，无进展生存期（PFS）显著延长。该病例突出了免疫治疗与化疗联合用于STK11突变NSCLC患者的潜在疗效和可行性。此外，我们还对文献报道的肺癌中STK11突变相关研究的最新进展进行了综述。
